Scrip Asks…What Does 2023 Hold For Biopharma? Part 6: Artificial Intelligence
Transforming Big Data Into Meaningful Outcomes For Health
The biopharma industry may not have been the fastest adopter of artificial intelligence, but its vast potential means companies of every shape and size know they cannot ignore it. Executives, advisors and investors share their predictions around the impact of AI in 2023.
You may also be interested in...
In this week's podcast version of Five Must-Know Things: Leqembi bodes well for Biogen; AbbVie predicts US Humira erosion; Sanofi’s R&D chief moves on; Roche’s ophthalmology plans; and Scrip Asks what 2023 holds for AI in pharma.
Artificial intelligence model’s comments signal the likely start of computer-generated comments to the US FDA’s public notices.
The European Commission’s newly-launched Cancer Imaging Initiative will see sophisticated digital technologies based on artificial intelligence used to speed up medical innovations as part of its wider Beating Cancer Plan.